334 results match your criteria Warfarin Dosing and VKORC1 CYP2C9


Effects of rs2260863 polymorphisms on warfarin maintenance dose in very elderly, frail Han-Chinese population.

Pharmacogenomics 2020 Jun 19. Epub 2020 Jun 19.

Department of Electrocardiogram Room, 900 Hospital of The Joint Logistics Team, 156 North Road, West 2nd Ring Road, Fuzhou, Fujian 350000, PR China.

This study was conducted to investigate the effects of , , and  and nongenetic factors on warfarin maintenance dose in a very elderly, frail Han-Chinese population.  16 variants of , , and were genotyped. Univariate analysis and multivariable regression model were performed for the associations of gene variants and warfarin maintenance dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2020-0054DOI Listing

Genotype-guided warfarin dosing may benefit patients with mechanical aortic valve replacements: randomized controlled study.

Sci Rep 2020 Apr 24;10(1):6988. Epub 2020 Apr 24.

College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, 52 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Korea.

This prospective, single-blind, randomized study was designed to evaluate the effect of genotype-based warfarin dosing compared with standard warfarin dosing in Korean patients with mechanical cardiac valves. Patients were assigned to either the genotype-based dosing group or the standard dosing group using stratified block randomization. The genotype-based dosing equation was adopted from a previous study which included VKORC1 rs9934438, CYP2C9 rs1057910, CYP4F2 rs2108622, and age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-63985-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181853PMC

A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study.

Front Pharmacol 2020 6;11:325. Epub 2020 Apr 6.

Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.

Background: Vitamin K antagonists (VKA) are used as prophylaxis for thromboembolic events in patients with cardiovascular diseases. The most common VKA are warfarin and acenocoumarol. These drugs have a narrow therapeutic margin and high inter-individual response variability due to clinical and pharmacogenetic variables. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2020.00325DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153463PMC

Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics.

Clin Transl Sci 2020 Apr 9. Epub 2020 Apr 9.

Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Precise dosing of warfarin is important to achieve therapeutic benefit without adverse effects. Pharmacogenomics explains some interindividual variability in warfarin response, but less attention has been paid to drug-drug interactions in the context of genetic factors. We investigated retrospectively the combined effects of cytochrome P450 (CYP)2C9 and vitamin K epoxide reductase complex (VKORC)1 genotypes and concurrent exposure to CYP2C9-interacting drugs on long-term measures of warfarin anticoagulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cts.12781DOI Listing
April 2020
2.110 Impact Factor

Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients.

Clin Appl Thromb Hemost 2020 Jan-Dec;26:1076029620909154

Laboratory of Chemical Carcinogenesis and Pharmacogenetics, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago, Chile.

Despite the development of new oral agents over the last decade, vitamin K antagonists (VKAs) remain the most widely used anticoagulants for treating and preventing thromboembolism worldwide. In Chile, the Ministry of Health indicates that acenocoumarol should be used in preference to any other coumarin. Complications of inappropriate dosing are among the most frequently reported adverse events associated with this medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1076029620909154DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288841PMC

[Verification of accuracy of warfarin stable dose prediction models in Shandong population].

Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2020 Apr;37(4):401-404

Qingdao Fuwai Cardiovascular Hospital, Qingdao, Shandong 266034, China.

Objective: To compare the accuracy of five warfarin-dosing algorithms and warfarin stable dose model (2.5 mg/day) for Shandong population.

Methods: One hundred and twenty five patients who achieved stable warfarin dose were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.1003-9406.2020.04.009DOI Listing

Genotype-guided warfarin therapy: Still of only questionable value two decades on.

Authors:
Rashmi R Shah

J Clin Pharm Ther 2020 Jun 13;45(3):547-560. Epub 2020 Mar 13.

Pharmaceutical Consultant, Gerrards Cross, UK.

What Is Known And Objective: Despite an apparently sound pharmacological basis, clinical studies of genotype-guided warfarin dosing have yielded mixed and conflicting results, leading to reluctance in its clinical implementation. The objective of this critique is to re-evaluate key warfarin pharmacogenetic studies with a view to explaining why this may be so.

Methods: Major widely-cited warfarin pharmacogenetic studies as well as recent meta-analyses were identified and a critical analysis of these was undertaken to identify factors that may account for poor clinical implementation of pre-treatment genotyping. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcpt.13127DOI Listing

Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting.

Front Pharmacol 2019 17;10:1527. Epub 2020 Jan 17.

Department of Cardiovascular Surgery, Fujian Medical University Union Hospital, Fuzhou, China.

The and genotypes are associated with anticoagulation control and the clinical events in warfarin therapy. However, the clinical utility of gene-based warfarin dosing (GBWD) is controversial. We compared the anticoagulation control and clinical events related to warfarin with GBWD to those with clinically fixed dosing (CFD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2019.01527DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988825PMC
January 2020

CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.

Pharmacogenomics J 2020 Feb 6. Epub 2020 Feb 6.

State Medical Academy, Nizhniy Novgorod, Russian Federation.

A total of 263 warfarin naive patients with indications to long-term anticoagulation were included in prospective multicenter study and randomized into Pharmacogenetics and Standard dosing groups. The loading warfarin dose in Pharmacogenetics group was calculated by Gage algorithm and corrected starting on day 5 of treatment according to INR. In Standard dosing group warfarin initial dose was 5 mg and starting on day 3 of treatment it was titrated according to INR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41397-020-0157-2DOI Listing
February 2020

Prioritizing rs7294 as a mirSNP contributing to warfarin dosing variability.

Pharmacogenomics 2020 03 24;21(4):257-267. Epub 2020 Jan 24.

Inter-University Centre for Genomics & Gene Technology, Department of Biotechnology, University of Kerala, Trivandrum-695 581, Kerala, India.

The role of mirSNPs in the 3'UTR of and genes that could influence warfarin dose variability via a discrete miRNA-mediated mechanism remains unexplained. Genotypic data in the 1000 Genomes dataset were analyzed for pair-wise linkage disequilibrium and allelic enrichment. MirSNP rs7294 in the 3'UTR of gene displayed varying strengths of linkage disequilibrium with rs9923231 and rs9934438 across populations, albeit consistently associated with higher warfarin dose requirements based on genome-wide association studies, meta-analysis and population-based association studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2019-0137DOI Listing

Genetic risk assessment towards warfarin application: Saudi Arabia study with a potential to predict and prevent side effects.

Saudi J Biol Sci 2020 Jan 23;27(1):456-459. Epub 2019 Nov 23.

Department of Pharmacy Practice, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Saudi Arabia.

Warfarin doses are greatly affected by polymorphism altering cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) gene. This study evaluated the prevalence of alleles (either single or double) and carriers of single nucleotide polymorphisms (SNPs) in both genotypes CYP2C9 and VKORC1 in alkharj area, Saudi Arabia and its association with warfarin use risk. Total 112 samples were collected and genotyped using FlexiGene DNA Kit for isolation and StepOnePlus Real-Time PCR System by TaqMan allelic discrimination methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sjbs.2019.11.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933267PMC
January 2020

Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations.

Pharmacotherapy 2020 02 14;40(2):142-152. Epub 2020 Jan 14.

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.

Objectives: Implementing pharmacogenetics for very important pharmacogenes (VIPs) holds the promise of improving clinical outcomes through optimal medication selection and dosing. However, significant differences in the frequency of actionable variants in VIPs may exist within subpopulations of a given ancestral group. Furthermore, these differences can potentially impact drug selection and dosing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/phar.2360DOI Listing
February 2020

Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.

Clin Pharmacol Ther 2020 Jun 28;107(6):1420-1433. Epub 2020 Jan 28.

Department of Molecular and Clinical Pharmacology, The Wolfson Centre for Personalized Medicine, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, UK.

Warfarin is the most commonly used oral anticoagulant in sub-Saharan Africa. Dosing is challenging due to a narrow therapeutic index and high interindividual variability in dose requirements. To evaluate the genetic factors affecting warfarin dosing in black-Africans, we performed a meta-analysis of 48 studies (2,336 patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217737PMC

Development and Validation of a Novel Warfarin Dosing Algorithm for Korean Patients With 1173C.

Ann Lab Med 2020 May;40(3):216-223

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Background: Differences in the performance of suggested warfarin dosing algorithms among different ethnicities and genotypes have been reported; this necessitates the development of an algorithm with enhanced performance for specific population groups. Previous warfarin dosing algorithms underestimated warfarin doses in 1173C carriers. We aimed to develop and validate a new warfarin dosing algorithm for Korean patients with 1173C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3343/alm.2020.40.3.216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933054PMC

The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population.

Pharmacogenomics J 2020 04 25;20(2):277-284. Epub 2019 Oct 25.

Qatar University, Doha, Qatar.

The objective of this study is to estimate the prevalence of VKORC1, CYP2C9, and CYP4F2 genetic variants and their contribution to warfarin dose variability in Qataris. One hundred and fifty warfarin-treated Qatari patients on a stable dose and with a therapeutic INR for at least three consecutive clinic visits were recruited. Saliva samples were collected using Oragene DNA self-collection kit, followed by DNA purification and genotyping via TaqMan Real-Time-PCR assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41397-019-0116-yDOI Listing

Personalised Warfarin Dosing in Children Post-cardiac Surgery.

Pediatr Cardiol 2019 Dec 5;40(8):1735-1744. Epub 2019 Oct 5.

Department of Pharmacy, University Hospitals of Leicester, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK.

Warfarin dosing is challenging due to a multitude of factors affecting its pharmacokinetics (PK) and pharmacodynamics (PD). A novel personalised dosing algorithm predicated on a warfarin PK/PD model and incorporating CYP2C9 and VKORC1 genotype information has been developed for children. The present prospective, observational study aimed to compare the model with conventional weight-based dosing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00246-019-02215-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848240PMC
December 2019
1 Read

Comparison of Two Different Techniques Of Warfarin Dosing Determination - A Chemometrics Study.

Iran J Pharm Res 2019 ;18(2):1010-1019

National Hemophilia Center, Department of Hematology and Transfusion Medicine, Faculty of Medicine of the Comenius University and University Hospital, Bratislava, Slovak Republic.

A high prevalence of genetic polymorphisms increases sensitivity to warfarin therapy. In this study, we investigated 47 patients with effective long-term therapy by warfarin well-controlled by monitoring of International Normalised Ratio (INR). All patients were tested for gene polymorphisms VKORC1, CYP2C9*C2, and CYP2C9*C3, which were used for a dose calculation employing a program www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.22037/ijpr.2019.1100653DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6706742PMC
January 2019
1 Read

Clinical Model for Predicting Warfarin Sensitivity.

Sci Rep 2019 09 6;9(1):12856. Epub 2019 Sep 6.

Easton Cardiovascular Associates, Easton, PA, USA.

Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the therapeutic dose. Complications from inappropriate warfarin dosing are one of the most common reasons for emergency room visits. Approximately one third of warfarin dose variability results from common genetic variants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-49329-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731233PMC
September 2019
2 Reads
5.078 Impact Factor

Impact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery.

Eur J Clin Pharmacol 2019 Dec 23;75(12):1685-1693. Epub 2019 Aug 23.

Department of Pharmacy, The First Hospital of Lanzhou University, Lanzhou, China.

Purpose: Factors influencing responsiveness to warfarin at treatment onset time were not well identified in Chinese patients undergoing heart valve replacement. We sought to select the most relevant factors that associated with patient response to warfarin early after heart valve surgery.

Methods: In this observational study, 289 patients starting warfarin therapy early after heart valve replacement surgery were enrolled. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00228-019-02747-5
Publisher Site
http://dx.doi.org/10.1007/s00228-019-02747-5DOI Listing
December 2019
3 Reads

Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.

Am J Health Syst Pharm 2019 02;76(6):387-397

Clinical Pharmacy Services, Marshfield Clinic Health Systems, Marshfield, WI.

Purpose: As a preliminary evaluation of the outcomes of implementing pharmacogenetic testing within a large rural healthcare system, patients who received pre-emptive pharmacogenetic testing and warfarin dosing were monitored until June 2017.

Summary: Over a 20-month period, 749 patients were genotyped for VKORC1 and CYP2C9 as part of the electronic Medical Records and Genomics Pharmacogenetics (eMERGE PGx) study. Of these, 27 were prescribed warfarin and received an alert for pharmacogenetic testing pertinent to warfarin; 20 patients achieved their target international normalized ratio (INR) of 2. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ajhp/article/76/6/387/5354462
Publisher Site
http://dx.doi.org/10.1093/ajhp/zxy072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479622PMC
February 2019
16 Reads

Analysis of Factors That Interrupt With INR Control in the First Anticoagulation Clinic Monitoring Jordanian Patients.

Clin Appl Thromb Hemost 2019 Jan-Dec;25:1076029619870252

3 Prince Iman Center for Research and Laboratory Sciences, King Hussein Medical Center (KHMC), Royal Medical Services (RMS), Amman, Jordan.

Multiple factors such as vitamin K consumption, drug interactions, herbs interactions, disease states, and alcohol intake affect international normalized ratio (INR) values and thus warfarin dosing. These variables have been described in general and for all patients in the literature. In contrast, the factors that affect INR control in a specific population are rarely studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1076029619870252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829640PMC
January 2020
5 Reads

Chinese Patients With Heart Valve Replacement Do Not Benefit From Warfarin Pharmacogenetic Testing on Anticoagulation Outcomes.

Ther Drug Monit 2019 12;41(6):748-754

Department of Clinical Laboratory, Wuhan Asia Heart Hospital, Wuhan University.

Background: Genotype-guided warfarin dosing has been shown in some randomized trials to improve anticoagulation outcomes in individuals of European ancestry; yet, its utility in Chinese patients with heart valve replacement remains unresolved.

Methods: A total of 2264 patients who underwent heart valve replacement at Wuhan Asia Heart Hospital were enrolled in this study. Patients were randomly divided into 2 groups, namely, a genotype-guided and a traditional clinically guided warfarin dosing group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000664DOI Listing
December 2019
5 Reads

Pharmacogenetics of Warfarin in a Diverse Patient Population.

J Cardiovasc Pharmacol Ther 2019 11 7;24(6):521-533. Epub 2019 May 7.

9 Department of Clinical Pharmacy, University of Southern California, Los Angeles, CA, USA.

Introduction: Many warfarin-related genotypes have shown to impact the average daily warfarin (ADW) dose requirements; however, information in non-Caucasian populations is limited.

Objectives: To identify the frequencies of 4 warfarin-related gene polymorphisms in an ethnically diverse patient population and to examine their impact with other clinical variables on ADW dose requirements.

Methods: Patients were recruited from 2 anticoagulation clinics in the Los Angeles area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1074248419843530DOI Listing
November 2019
8 Reads

Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics.

Pharmacogenomics 2019 06 3;20(8):599-608. Epub 2019 May 3.

David Weatherall Chair of Medicine, University of Liverpool & Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2019-0021DOI Listing
June 2019
2 Reads

Extremely low therapeutic doses of acenocoumarol in a patient with and genotype.

Pharmacogenomics 2019 04 15;20(5):311-317. Epub 2019 Apr 15.

Molecular Immunopathology & Histocompatibility Unit, Onassis Cardiac Surgery Center, Athens, Greece.

Vitamin-K antagonists (VKAs) have remained the mainstay of oral anticoagulant therapy for the treatment and prevention of thromboembolism. The management of treatment with VKAs is challenging due to their narrow therapeutic index and the wide interindividual variation in response to therapy. Variants of the and the gene account for 30-50% of the variability in dosing requirements, and it has been proposed that genotyping of these loci could facilitate management of VKA therapy and minimize risk of overanticoagulation, even in very low doses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0189DOI Listing
April 2019
6 Reads

Warfarin dose requirement in patients having severe thrombosis or thrombophilia.

Br J Clin Pharmacol 2019 08 17;85(8):1684-1691. Epub 2019 Jun 17.

Coagulation Disorders Unit, Clinical Chemistry, University of Helsinki and HUSLAB, Helsinki University Hospital, Helsinki, Finland.

Aims: Warfarin dose requirement varies significantly. We compared the clinically established doses based on international normalized ratio (INR) among patients with severe thrombosis and/or thrombophilia with estimates from genetic dosing algorithms.

Methods: Fifty patients with severe thrombosis and/or thrombophilia requiring permanent anticoagulation, referred to the Helsinki University Hospital Coagulation Center, were screened for thrombophilias and genotyped for CYP2C9*2 (c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624394PMC
August 2019
19 Reads

The Genetics of Warfarin Dose-Response Variability in Africans: An Expert Perspective on Past, Present, and Future.

OMICS 2019 03;23(3):152-166

1 Pharmacogenomics and Drug Metabolism Research Group, Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Coumarins such as warfarin are prescribed for prevention and treatment of thromboembolic disorders. Warfarin remains the most widely prescribed and an anticoagulant of choice in Africa. Warfarin use is, however, limited by interindividual variability in pharmacokinetics and a narrow therapeutic index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/omi.2019.0018DOI Listing
March 2019
8 Reads
2.362 Impact Factor

Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.

Clin Pharmacokinet 2019 08;58(8):1077-1089

Department of Biopharmaceutics, Meiji Pharmaceutical University, Noshio 2-522-1, Kiyose, Tokyo, 204-8588, Japan.

Background: Population differences in warfarin dosing requirement have been reported; however, unlike the pharmacokinetics (PK) of warfarin, the quantitative influences of pharmacodynamic (PD) factors on the anticoagulation response to warfarin in different ethnic populations are totally unknown.

Methods: Using population PK/PD analysis, we attempted to identify predictors of S-warfarin clearance [CL(S)] and half maximal effective concentration (EC) to quantify racial differences in both PK and PD parameters, and to assess the contribution of these parameters to the international normalized ratio (INR) and over-anticoagulation response (INR ≥ 4) in a cohort of 309 White, Asian and African American patients.

Results: Similar to our previous findings, the median CL(S) was 30% lower in African American patients than Asian and White patients (169 vs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40262-019-00745-5
Publisher Site
http://dx.doi.org/10.1007/s40262-019-00745-5DOI Listing
August 2019
19 Reads

Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.

Mol Biol Rep 2019 Apr 2;46(2):1825-1833. Epub 2019 Feb 2.

Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

It was aimed to underline the importance and explain the meaning of genetic testing in warfarin dosing and investigate and evaluate the contributions of the CYP2C9, VKORC1, and CYP4F2 variants in a Turkish population. Two hundred patients were genotyped for CYP2C9 (rs1799853, rs1057910 and rs56165452), VKORC1 (rs9934438, rs8050894, rs9923231, rs7294 and rs2359612) and CYP4F2 (rs2108622), yet, only 127 patients were found suitable for further evaluation in terms of their personal response to warfarin due to long term usage and available INR and dose usage information. The DNA sequences were determined by the ABI PRISM 3100 Genetic Analyzer to 3130xl System (Applied Biosystems, Foster City, California). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11033-019-04634-9
Publisher Site
http://dx.doi.org/10.1007/s11033-019-04634-9DOI Listing
April 2019
21 Reads

Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.

J Cardiovasc Pharmacol 2019 03;73(3):127-135

Department of Cardiology, The First Affiliated Hospital, Jinan University, Guangzhou, China.

Aims: To evaluate the efficacy and safety of using genetic information to guide warfarin dosing in the Chinese population.

Methods: This meta-analysis was conducted among the published, randomized, controlled trials (RCTs) in the Chinese population comparing genotype-guided warfarin dosing (PG group) with clinical or standard warfarin dosing (STD group). RCTs published on or before January 2018 were identified using the PubMed, Embase, Cochrane Library, CNKI, Chinese VIP database, and Chinese Wanfang database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000656DOI Listing
March 2019
1 Read

Pharmacogenomics research and clinical implementation in Brazil.

Basic Clin Pharmacol Toxicol 2019 May 24;124(5):538-549. Epub 2019 Jan 24.

Research Division, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.

We searched PubMed entries and the Lattes database of Brazilian Pharmacogenetics Network investigators, for pharmacogenetic/genomic (PGx) studies in the Brazilian population, focusing on the drugs and genes included in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines. Warfarin was the most extensively studied drug in a PGx context: a genomewide association study targeting warfarin stable dose identified significant signals in VKORC1 and CYP2C9, several PGx dosing algorithms were developed based on these and other genes, and the implications of population admixture on extrapolation of dosing recommendations in the CPIC guidelines were examined. A study in renal transplanted patients disclosed association of CYP3A5*6 and CYP3A5*7 with tacrolimus dosing, which led to addition of these variants to CYP3A5*3 in the CPIC tacrolimus guideline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcpt.13196DOI Listing
May 2019
9 Reads

Warfarin Dose and CYP2C Gene Cluster: An African Ancestral-Specific Variant Is a Strong Predictor of Dose in Black South African Patients.

OMICS 2019 01 19;23(1):36-44. Epub 2018 Dec 19.

1 Pharmacogenomics and Drug Metabolism Research Group, Division of Human Genetics, Department of Pathology & Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town , Cape Town, South Africa .

Warfarin is a widely prescribed anticoagulant with a narrow therapeutic index. The rs12777823G>A single-nucleotide polymorphism (SNP) in the CYP2C gene cluster has been shown to influence optimal warfarin doses in African Americans. We report here effects of rs12777823G>A SNP on warfarin dose requirements in two South African population groups, black Africans (BA) and mixed ancestry (MA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/omi.2018.0174DOI Listing
January 2019
10 Reads
2.362 Impact Factor

Pharmacogenetic considerations of anticoagulant medication.

J Physiol Pharmacol 2018 Aug 10;69(4). Epub 2018 Nov 10.

Department of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland.

Predicting the clinical consequences of anticoagulant therapy by identifying gene variants could help in the risk assessment of thrombosis or bleeding before and after surgery and may result in choosing more beneficial therapy. This work provides an overview of pharmacogenetic data of commonly used anticoagulant medication. The review focuses on polymorphisms influencing the efficacy and safety of the parenteral and oral anticoagulants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26402/jpp.2018.4.01DOI Listing
August 2018
38 Reads

Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients.

Pharmgenomics Pers Med 2018 16;11:169-178. Epub 2018 Oct 16.

GENIUROS Research Group, Center For Research in Genetics and Genomics - CIGGUR, School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia,

Purpose: Warfarin is an oral anticoagulant associated with adverse reaction to drugs due to wide inter- and intra-individual dosage variability. Warfarin dosage has been related to non-genetic and genetic factors. and gene polymorphisms affect warfarin metabolism and dosage. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/creating-and-validating-a-warfarin
Publisher Site
http://dx.doi.org/10.2147/PGPM.S170515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198877PMC
October 2018
29 Reads

Pharmacogenetics of warfarin dosing in patients of African and European ancestry.

Pharmacogenomics 2018 11 22;19(17):1357-1371. Epub 2018 Oct 22.

Department of Neurology, School of Medicine, University of Alabama at Birmingham, AL 35294, USA.

Despite the introduction of direct acting oral anticoagulants, warfarin remains the most commonly prescribed oral anticoagulant. However, warfarin therapy is plagued by the large inter- and intrapatient variability. The variability in dosing fueled research to identify clinical and genetic predictors and develop more accurate dosing algorithms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2018-0146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562764PMC
November 2018
7 Reads

Ensemble of machine learning algorithms using the stacked generalization approach to estimate the warfarin dose.

PLoS One 2018 19;13(10):e0205872. Epub 2018 Oct 19.

Easton Cardiovascular Associates, Easton, PA, United States of America.

Warfarin dosing remains challenging due to narrow therapeutic index and highly individual variability. Incorrect warfarin dosing is associated with devastating adverse events. Remarkable efforts have been made to develop the machine learning based warfarin dosing algorithms incorporating clinical factors and genetic variants such as polymorphisms in CYP2C9 and VKORC1. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0205872PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195267PMC
April 2019
16 Reads
3.234 Impact Factor

Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.

Thromb Res 2018 11 1;171:167-170. Epub 2018 Oct 1.

Institute of Cellular Medicine, Newcastle University and Newcastle upon Tyne Hospitals, NHS Foundation Trust, Newcastle upon Tyne, NE1 7RU, UK. Electronic address:

Introduction: Warfarin therapy is stopped for a fixed period prior to surgery to minimise risk of perioperative bleeding. However, anticoagulation subsides at varying rates among different patients. We evaluated the influence of genetic (CYP2C9 and VKORC1), patient and clinical factors on warfarin clearance and the decline in INR following warfarin withdrawal. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00493848183055
Publisher Site
http://dx.doi.org/10.1016/j.thromres.2018.09.064DOI Listing
November 2018
31 Reads
2.447 Impact Factor

Genotype-Guided Warfarin Dosing in Patients With Mechanical Valves: A Randomized Controlled Trial.

Ann Thorac Surg 2018 12 8;106(6):1774-1781. Epub 2018 Sep 8.

Division of Cardiac Surgery, Key Laboratory on Assisted Circulation, Ministry of Health, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address:

Background: The clinical utility of genotype-guided warfarin dosing remains controversial. The objective of this trial was to evaluate the efficacy and safety of genotype-guided warfarin dosing in East Asians.

Methods: A double-blind, randomized control trial was performed to compare a genotype-guided dosing algorithm (CYP2C9, VKORC1, and CYP4F2) with a clinical-guided one in the initiation treatment for patients with mechanical heart valves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2018.07.026DOI Listing
December 2018
18 Reads

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective.

JACC Basic Transl Sci 2018 Aug 28;3(4):545-549. Epub 2018 Aug 28.

Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.

The U.S. Food and Drug Administration recently marked 10 years since first updating the labeling for warfarin (often referred to as the "poster child" of pharmacogenomics) to include information regarding the potential impact of and genetic variation on warfarin dosing requirements and risks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacbts.2018.06.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115648PMC
August 2018
8 Reads

Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China.

Pediatr Cardiol 2019 Jan 18;40(1):29-37. Epub 2018 Aug 18.

Department of Cardiology, Children's Hospital of Chongqing Medical University; Ministry of Education Key Laboratory of Child Development and Disorders, 136# Zhongshan 2nd Rd. Yuzhong District, Chongqing, 400014, China.

Long-term oral warfarin is recommended in pediatric Kawasaki disease patients with large coronary artery aneurysms; however, heterogeneity is considerable. This study aimed to determine variables affecting warfarin dosage in Kawasaki disease. The enrolled individuals (194 children) were divided into four groups: (1) Cases with severe coronary artery lesions (CAL) of IV to V degrees or thrombogenesis treated with oral warfarin were assigned to Group A; (2) Group B, CAL of I degrees; (3) Group C, CAL of II and III degrees cases with small or medium-sized CAL not treated with warfarin; (4) Group D, normal children without Kawasaki disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00246-018-1957-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348293PMC
January 2019
28 Reads

Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial.

BMC Med 2018 07 10;16(1):104. Epub 2018 Jul 10.

Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.

Background: Genotype-guided warfarin dosing has been shown in some randomized trials to improve anticoagulation outcomes in individuals of European ancestry, yet its utility in Asian patients remains unresolved.

Methods: An open-label, non-inferiority, 1:1 randomized trial was conducted at three academic hospitals in South East Asia, involving 322 ethnically diverse patients newly indicated for warfarin (NCT00700895). Clinical follow-up was 90 days. Read More

View Article

Download full-text PDF

Source
https://bmcmedicine.biomedcentral.com/articles/10.1186/s1291
Publisher Site
http://dx.doi.org/10.1186/s12916-018-1093-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038204PMC
July 2018
49 Reads
6 Citations
7.249 Impact Factor

The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study.

J Thromb Haemost 2018 09 17;16(9):1732-1742. Epub 2018 Jul 17.

Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.

Essentials A pediatric pharmacogenetic dosing algorithm for acenocoumarol has not yet been developed. We conducted a multicenter retrospective follow-up study in children in the Netherlands. Body surface area and indication explained 45. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jth.14211DOI Listing
September 2018
26 Reads

Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study.

Blood Coagul Fibrinolysis 2018 Sep;29(6):496-500

Clinical Pharmacology Section, Internal Medicine Department.

: Coumadin oral anticoagulants are widely used in multiple clinical scenarios. Their narrow therapeutic range and a dosing strategy based on 'a posteriori' algorithms, pose them as an interesting group for prediction modelling research. Extensive literature explaining the association between clinical and genetic variables with the dose of warfarin have been published. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00001721-201809000-0000
Publisher Site
http://dx.doi.org/10.1097/MBC.0000000000000746DOI Listing
September 2018
13 Reads

Weight and the vitamin K expoxide reductase 1 genotype primarily contribute to the warfarin dosing in pediatric patients with Kawasaki disease.

Thromb Res 2018 07 8;167:32-36. Epub 2018 May 8.

Pediatric Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China. Electronic address:

Introduction: Warfarin therapy is recommended in children with giant coronary artery aneurysms (GCAAs) after Kawasaki disease (KD). Large individual variability makes it difficult to predict the warfarin dose. Polymorphisms in the vitamin K expoxide reductase 1 (VKORC1) and cytochrome P4502C9 (CYP2C9) genes have been reported to influence the warfarin dose. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2018.05.002DOI Listing
July 2018
14 Reads
2.450 Impact Factor

Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials.

Br J Clin Pharmacol 2018 09 21;84(9):1868-1882. Epub 2018 Jun 21.

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, 300211, People's Republic of China.

Aims: Previous trials on the effectiveness of genotype-guided warfarin dosing vs. conventional dosing have been inconclusive. We conducted a systematic review and meta-analysis of randomized trials comparing genotype-guided to conventional dosing strategies. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bcp.13621
Publisher Site
http://dx.doi.org/10.1111/bcp.13621DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089819PMC
September 2018
45 Reads
3 Citations
3.880 Impact Factor

The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.

Indian J Hematol Blood Transfus 2018 04 27;34(2):328-336. Epub 2016 Sep 27.

3Biochemistry Department, Pharos University in Alexandria, Alexandria, Egypt.

Warfarin is the most commonly used drug for chronic prevention of thromboembolic events, it also ranks high among drugs that cause serious adverse events. The variability in dose requirements has been attributed to inter-individual differences in medical, personal, and genetic factor. Cytochrome P-450 2C9 is the principle enzyme that terminates the anticoagulant effect of warfarin by catalyzing the conversion of the pharmacologically more potent S-enantiomer to its inactive metabolites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-016-0725-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884968PMC
April 2018
10 Reads

Warfarin Dosing According to the Genotype-guided Algorithm is Most Beneficial in Patients With Atrial Fibrillation: A Randomized Parallel Group Trial.

Ther Drug Monit 2018 06;40(3):362-368

Department for Pharmacogenomics and Therapy Individualization, University Hospital Center Zagreb, Zagreb, Croatia.

Background: Observational studies have indicated potential benefits of CYP2C9- and VKORC1-guided dosing of warfarin but randomized clinical trials have resulted in contradictory findings. One of the reasons for contradiction may be the negligence of possible differences between warfarin indications. This study aims to determine efficacy and safety of genotype-guided and clinically guided dosing of warfarin in atrial fibrillation (AF), deep-vein thrombosis (DVT), and pulmonary embolism (PE) within the first 5 days after the introduction of therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0000000000000501DOI Listing
June 2018
35 Reads

Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.

Cardiovasc Ther 2018 Apr 3;36(2). Epub 2018 Jan 3.

Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.

Aim: This study was conducted to compare predictive accuracy of the available pharmacogenetics (PGx)-guided warfarin dosing algorithms derived from Caucasian, Asian, and mixed population to identify a suitable algorithm for Thai population.

Methods: Ten warfarin dosing algorithms derived from different population including Caucasian, East Asian, South-East Asian, and mixed races were selected and tested with clinical and genetic data of Thai patients. Comparative performances of these algorithms were tested using mean dose error (MDE) between actual warfarin maintenance dose (AWMD) and predicted dose generated by each dosing algorithm, and percentage of ideal dose prediction (IDP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1755-5922.12315DOI Listing
April 2018
20 Reads

Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.

Lab Med 2017 Dec;49(1):25-34

Department of Cardiac Surgery, Madani Heart Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.

Many lines of evidence suggest that warfarin dosing variability is significantly associated with cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1) variant alleles. Therefore, we investigated the influence of CYP2C9*2 (430C/T), *3 (1075A/C) and VKORC1 (-1639G/A) polymorphisms on warfarin dose requirements in patients who underwent cardiac valve surgery during the postoperative period.A total of 100 patients with heart valve replacement who had a prescribed target international normalized ratio (INR) range of 2-3 were enrolled in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/labmed/lmx072DOI Listing
December 2017
33 Reads